Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C8H10AsN2O4.Na |
| Molecular Weight | 296.0874 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].NC(=O)CNC1=CC=C(C=C1)[As](O)([O-])=O
InChI
InChIKey=UEYIAABRKWHXJV-UHFFFAOYSA-M
InChI=1S/C8H11AsN2O4.Na/c10-8(12)5-11-7-3-1-6(2-4-7)9(13,14)15;/h1-4,11H,5H2,(H2,10,12)(H2,13,14,15);/q;+1/p-1
| Molecular Formula | Na |
| Molecular Weight | 22.98976928 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C8H10AsN2O4 |
| Molecular Weight | 273.0976 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Tryparsamide is an arsenic compound with activity against Spirochaetes bacteria. Tryparsamide is used in the treatment of syphilis and African sleeping sickness. For decades Tryparsamide remained the standard treatment for trypanosomiasis. Tryparsamide has two remarkable properties: first, it increases the resistance of the individual by improving his general physical status; and, second, the high penetrability for nervous tissue which it possesses may increase the potential spirocheticidal action of the drug.
CNS Activity
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| The present status of tryparsamide in syphilotherapy. | 1947-05 |
|
| General Discussion on Tryparsamide and Stovarsol: Meeting of The Medical Society for the Study of Venereal Diseases. London. July 13th, 1940. | 1941-01 |
|
| Comparison of the Toxicity of Tryparsamide and Neocryl in the Treatment of Neurosyphilis. | 1940-08-31 |
|
| Tryparsamide Therapy of Neurosyphilis in Negroes. | 1931-07 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20315250
The proper dosage for the average individual is to 3 grams of the drug. This amount dissolved in 10-20 cc. of sterile distilled water is given weekly. It may be given subcutaneously, intramuscularly or intravenously. The intravenous route is the preferable one to use. It should be given slowly by the syringe method.
Route of Administration:
Parenteral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:01:50 GMT 2025
by
admin
on
Mon Mar 31 18:01:50 GMT 2025
|
| Record UNII |
4NN21HAX16
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C52588
Created by
admin on Mon Mar 31 18:01:50 GMT 2025 , Edited by admin on Mon Mar 31 18:01:50 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
435
Created by
admin on Mon Mar 31 18:01:50 GMT 2025 , Edited by admin on Mon Mar 31 18:01:50 GMT 2025
|
PRIMARY | |||
|
C66646
Created by
admin on Mon Mar 31 18:01:50 GMT 2025 , Edited by admin on Mon Mar 31 18:01:50 GMT 2025
|
PRIMARY | |||
|
2050
Created by
admin on Mon Mar 31 18:01:50 GMT 2025 , Edited by admin on Mon Mar 31 18:01:50 GMT 2025
|
PRIMARY | |||
|
209-070-9
Created by
admin on Mon Mar 31 18:01:50 GMT 2025 , Edited by admin on Mon Mar 31 18:01:50 GMT 2025
|
PRIMARY | |||
|
23665572
Created by
admin on Mon Mar 31 18:01:50 GMT 2025 , Edited by admin on Mon Mar 31 18:01:50 GMT 2025
|
PRIMARY | |||
|
DTXSID301046341
Created by
admin on Mon Mar 31 18:01:50 GMT 2025 , Edited by admin on Mon Mar 31 18:01:50 GMT 2025
|
PRIMARY | |||
|
C073345
Created by
admin on Mon Mar 31 18:01:50 GMT 2025 , Edited by admin on Mon Mar 31 18:01:50 GMT 2025
|
PRIMARY | |||
|
554-72-3
Created by
admin on Mon Mar 31 18:01:50 GMT 2025 , Edited by admin on Mon Mar 31 18:01:50 GMT 2025
|
PRIMARY | |||
|
m11244
Created by
admin on Mon Mar 31 18:01:50 GMT 2025 , Edited by admin on Mon Mar 31 18:01:50 GMT 2025
|
PRIMARY | Merck Index | ||
|
3636
Created by
admin on Mon Mar 31 18:01:50 GMT 2025 , Edited by admin on Mon Mar 31 18:01:50 GMT 2025
|
PRIMARY | |||
|
4NN21HAX16
Created by
admin on Mon Mar 31 18:01:50 GMT 2025 , Edited by admin on Mon Mar 31 18:01:50 GMT 2025
|
PRIMARY | |||
|
100000077468
Created by
admin on Mon Mar 31 18:01:50 GMT 2025 , Edited by admin on Mon Mar 31 18:01:50 GMT 2025
|
PRIMARY | |||
|
SUB11359MIG
Created by
admin on Mon Mar 31 18:01:50 GMT 2025 , Edited by admin on Mon Mar 31 18:01:50 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
SOLVATE->ANHYDROUS |